

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335368880 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 30, 2004

Signature: Tia B. Zimmerman

(Tia B. Zimmerman)

PATENT

Docket No. 304142000321

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Malaya CHATTERJEE et al.

Serial No.: 08/766,350

Filing Date: December 13, 1996

For: MURINE ANTI-IDIOTYPE ANTIBODY  
11D10 AND METHODS OF USE  
THEREOF

Examiner: S. Rawlings

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

07/07/2004 NROCHA1 00000017 031952 08766350

02 FC:1806

100.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for

any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 304142000321. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: 6/30, 2004


Respectfully submitted,

By: *Jill A. Jacobson*  
Jill A. Jacobson  
Registration No. 40,030  
Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5876  
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 304142000321

Application Number 08/766,350


**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

Applicant

Malaya CHATTERJEE et al

Filing Date December 13, 1996

Group Art Unit 1642

Mailing Date June 30, 2004

**U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/14/2001	6,274,143	Chatterjee et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	08/08/1991	WO 91/11508	WIPO			
	3.	05/29/1992	WO 92/08495	WIPO			
	4.	05/23/2002	WO 02/40501	WIPO			

**OTHER DOCUMENTS**

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	5.	Amalfitano, A. et al. (2002). "Separating Fact From Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy," <i>Current Gene Therapy</i> 2(2):111-133.
	6.	Benvenuti, F. et al. (2000). "Anti-idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection," <i>Gene Therapy</i> 7(7):605-611.
	7.	Benvenuti, F. et al. (2001). "Anti-idiotypic Antibodies Induced by Genetic Immunisation are Directed Exclusively Against Combined VL/VH Determinants," <i>Gene Therapy</i> 8(20):1555-1561.
	8.	Berzoksky, J.A. and Berkower, I.I. (1993). "Immunogenicity and Antigen Structure," Chapter 8 <i>In Fundamental Immunology</i> , William E. Paul ed., Raven Press NY, page 242.
	9.	Bodey, B. et al. (2000). "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Research</i> 20:2665-2676.
	10.	Browning, J. L. et al. (1993). "Lymphotoxin $\beta$ , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," <i>Cell</i> (72):847-856.
	11.	Darsley, M. J. et al. (1985). "Nucleotide Sequences of Five Anti-Lysozyme Monoclonal Antibodies," <i>EMBO J.</i> 4(2):393-398.
	12.	De Waele, P. et al. (1988). "Expression in Non-Lymphoid Cells of Mouse Recombinant Immunoglobulin Directed Against The Tumour Marker Human Placental Alkaline Phosphatase," <i>Eur. J. Biochem.</i> 176:287-295.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 304142000321

Application Number 08/766,350

Applicant

Malaya CHATTERJEE et al


Filing Date December 13, 1996

Group Art Unit 1642

Mailing Date June 30, 2004

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)



13.	Gavilondo, J.V. et al. (2000). "Antibody Engineering at the Millennium," <i>Biotechniques</i> 29(1): 128-145.
14.	Houdebine, L-M. (1994). "Production of Pharmaceutical Proteins From Transgenic Animals," <i>Journal of Biotechnology</i> 34:269-287.
15.	Kavaler, J. et al. (1990). "A Set of Closely Related Antibodies Dominates The Primary Antibody Response To The Antigenic Site CB of The A/PR/8/34 Influenza Virus Hemagglutinin," <i>J. Immun.</i> 145(7):2312-2321.
16.	Kennedy, R. C. et al. (1985). "Vaccines Utilizing Internal Image Anti-Idiotypic Antibodies that Mimic Antigens of Infectious Organisms," <i>Biotechniques</i> 3(5):404-410.
17.	Liu, A. Y. et al. (1987). "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity," <i>J. Immunol.</i> 139(10):3521-3526.
18.	Mo, J. A. et al. (1993). "Variable Region Gene Selection of Immunoglobulin G-Expressing B Cells With Specificity For a Defined Epitope On Type II Collagen," <i>Eur. J. Immunol.</i> 23:2503-2510.
19.	Pandha, H. S et al. (2000). "Oncological Applications of Gene Therapy," <i>Current Opinion in Investigation Drugs</i> 1(1):122-134.
20.	Pandya, K. J. et al. (1985). "A Retrospective Study of Earliest Indicators of Recurrence in Patients On Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials For Breast Cancer. A Preliminary Report," <i>Cancer</i> 55(1):202-205.
21.	Patterson, A. P. (2003). "Principles Investigators for Human Gene Transfer Trials Employing Retroviral Vectors. Notification of a Serious Adverse Event. <u>Department of Health and Human Service</u> , pp.1-3.
22.	Reeck et al. (1987). "Homology," Protein and Nucleic Acids: A Terminology Muddle and Way out of It," <i>Cell</i> 50(5):667.
23.	Schouten, D. et al. (1993). "Development of Lipoprotein-like Lipid Particles for Drug Targeting Neo-High Density Lipoproteins," <i>Molecular Pharmacology</i> 44(2):486-492.
24.	Seidman, J. G. et al. (1979). "A $\kappa$ -Immunoglobulin Gene is Formed by Site-Specific Recombination without Further Somatic Mutation," <i>Nature</i> 280(5721):370-375.
25.	Shlomchik, M. et al. (1990). "Anti-DNA Antibodies from Autoimmune Mice Arise by Clonal Expansion and Somatic Mutation," <i>J. Exp. Med.</i> 171(1):265-297.
26.	Stevenson, F. K. et al. (1995). "Idiotypic DNA Vaccines Against B-Cell Lymphoma," <i>Immunological Reviews</i> 145:211-228.
27.	Zeytin, H. E. et al. (2000). "Construction and Characterization of DNA Vaccines Encoding the Single-Chain Variable Fragment of the Anti-Idiotypic Antibody 1A7 Mimicking the Tumor-Associated Antigen Disialoganglioside GD2," <i>Cancer Gene Ther.</i> 7(11):1426-1436.
28.	Verma, I. M. et al. (1997). "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

pa- 746601